SLC5A2 and type 2 diabetes mellitus: Based on these results, the newly-updated treatment guidelines of the ADA recommend considering the use of SGLT2 inhibitors with proven benefits, especially in patients with T2D and concomitant HF, independent of glycemic control and background metformin therapy [13].